CHICAGO, Jan. 8, 2013 /PRNewswire/ -- ICAP Patent Brokerage is searching for a buyer for a patented therapeutic approach from Nour Heart, Inc. This portfolio is currently available for sale and includes methods for a combined therapy to treat and protect against inflammation and cell death (apoptosis) in conditions such as heart attack and stroke. In addition to cardioprotection and neuroprotection benefits, this safe, innovative therapy can also be formulated for use in sports supplements.
"We are excited to offer this therapeutic and protective medicine tool to our global base of buyers. Heart disease and high-blood pressure ailments are reaching epidemic levels, and, as a result of this growing medical and market need, the therapy for sale has the potential to revolutionize and become the new standard for treating and protecting against the damage that occurs after heart attack, stroke, and other trauma," says Dean Becker, CEO of ICAP Patent Brokerage.
Key Characteristics & Benefits
Heart attack and stroke are the first and third leading causes of death for men and women, and are among the most widespread and costly health problems facing our nation today. Both occur as a result of ischemia, or reduction of blood flow, to the heart and brain. Inflammation is a hallmark of tissue response to ischemic injury. The inflammation, if left untreated, can lead to a cascade of increasingly dangerous issues beginning with tissue injury and slow cell death, followed by necrosis, organ failure, and death.
When a patient is in crisis, healthcare providers must work quickly to provide critical care to stop damage and ultimately save the life of the patient. The IP package for sale offers healthcare providers with a combined protective treatment option, which reduces inflammation and slows or prevents cell death, thus combating the symptoms and issues associated with heart attack, stroke, and trauma. Further, the therapy can be administered orally or via injection depending on the situation and characteristics of the patient or end-user.
Studies have shown that when this new therapy is administered before the initiation of trauma, the agents have a favorable effect and can protect the tissues from harm, prevent further damage, and restore organ function. When such agents are administered after the traumatic episode they can inhibit the destructive injury cascade and result in restoration of organ function.
In addition to applications for high-risk patients, this safe and innovative therapy can also be formulated for inclusion in supplements to boost energy for athletes and health-conscious individuals wishing to reap the benefits of protective care. This IP package will be of interest to healthcare firms operating in cardioprotection, neuroprotection, or the production of sports supplements.
Companies who have cited this portfolio include: Amira Pharmaceuticals Inc., Avicena Group Inc., Johnson & Johnson, Medtronic, Inc., Institute of Cancer Research, The Original Creatine Patent Co. Ltd., Bio-Botanica, Inc., Dana-Farber Cancer Institute Inc., and the University of California.
The technical description of this IP sales offering includes information regarding the specific medical agents employed, applications, and selected patent details.
To learn more about the assets available for sale in this portfolio:
Contact Dean Becker of ICAP Patent Brokerage at (561) 309-0011 or via email at Dean.Becker@us.icap.com.
About ICAP Patent Brokerage
ICAP Patent Brokerage is a division of ICAP plc and the world's largest intellectual property brokerage and patent auction firm.
ICAP is the world's leading interdealer broker and provider of post trade risk and information services. The Group matches buyers and sellers in the wholesale markets in interest rates, credit, commodities, FX, emerging markets and equity derivatives through voice and electronic networks. Through our post trade risk and information services we help our customers manage and mitigate risks in their portfolios. For more information, go to www.icap.com.
SOURCE ICAP Patent Brokerage